With a review pending, the state's stem cell agency looks for new leadership, new therapies and more money
By David Jensen,
The Sacramento Bee
| 11. 28. 2010
[Op-Ed]
Lured by visions of nearly magical medical solutions for everything from cancer to Alzheimer's, California voters six years ago approved a plan to borrow billions of dollars to pay scientists to look into human embryonic stem cell research.
Today the unprecedented $3 billion research effort by the California Institute for Regenerative Medicine faces a watershed moment, including the most sweeping review yet of its progress along with the departure of the man whose name has become synonymous with California stem cell research. Additionally, leaders of the program are pressing hard for concrete results that will persuade voters to cough up billions more to continue the effort.
This confluence of self-examination and changing of the guard comes amid criticism over the agency's promise of transparency and openness as it operates independently from oversight of the governor and Legislature; conflicts of interest by a board of directors who have directed $1 billion in grants to universities and research enterprises to which they have links; and the fact that no embryonic stem cell therapy is ready for patients, although the 2004 campaign for...
Related Articles
By Gregory Laub and Hannah Glaser, MedPage Today | 08.07.2025
In this MedPage Today interview, Leigh Turner, PhD, a professor of health policy and bioethics at the University of California Irvine, unpacks the growing influence of stem cell clinics and the blurred line between medicine and marketing. He explains how...
By Gina Kolata, The New York Times | 06.20.2025
A single infusion of a stem cell-based treatment may have cured 10 out of 12 people with the most severe form of type 1 diabetes. One year later, these 10 patients no longer need insulin. The other two patients need...
By Christina Jewett, The New York Times | 06.05.2025
Health Secretary Robert F. Kennedy Jr. recently declared that he wanted to expand access to experimental therapies but conceded that they could be risky or fraudulent.
In a podcast with Gary Brecka, who describes himself as a longevity expert...
By Mike Baker, The New York Times | 02.25.2025
As investigators struggled for weeks to find who might have committed the brutal stabbings of four University of Idaho students in the fall of 2022, they were focused on a key piece of evidence: DNA on a knife sheath that...
